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RESPONSE: ASSESSING THE INSTRUMENTS
Jack D. Blaine, M.D.; Robert F. Forman, Ph.D.; and Dace Svikis, Ph.D.
Jack Blaine:Except for the ASI, the instru-
ments discussed in the article (Samet et al.,
2007) were developed for research. The
AUDADIS, as the authors note, was cre-
ated for use in large-scale epidemiological
research in the general population. It’s a very
fine, fully structured interview. A research
assistant with no clinical training can make
valid diagnoses. The SCID and the PRISM
were developed to be administered by expe-
rienced clinicians. These interviews take
longer, though, so they’re not practical for
larger-scale research. The CIDI was also
developed for epidemiological research,
though we use it in clinical settings.
Dace Svikis: In research, we use these for-
mal structured assessment instruments to
characterize our population. As the authors
illustrate with their example of depression
studies, we need to know what substance
use and other psychiatric diagnoses partic-
ipants have so that our analyses don’t miss
any factors that affect outcomes.
Robert Forman: The use of formal struc-
tured assessment instruments is absolutely
critical for research. Even in research, how-
ever, they must be used judiciously, because
patients’ reactions to them can affect clini-
cal outcomes and possibly confound the
interpretation of results (e.g., Clifford, Maisto,
and Davis, 2007). To me, the justification
for using them in clinical practice hasn’t
been established.
Blaine:Except for the ASI, the instruments
discussed in the article take too much time
to administer to be practical for routine clin-
ical use. They also often require extensive
training and monitoring for fidelity to ensure
that clinicians continue to use the measures
in line with the practice guidelines.
Data quality and therapeutic alliance
Svikis:The move toward the clinical use of
standardized instruments was spearheaded
by concern that some clinicians were not
doing a thorough job of collecting patient
information. Dr. A. Thomas McLellan has
said that this was his original motivation for
developing the ASI. He had noted that, for
example, some clinicians were asking patients
about depression, and others weren’t.
Standardized instruments make sure that
all clinicians obtain a uniform set of basic
patient data. At the same time, we need to
recognize that there are many really good
drug counselors with excellent clinical skills.
Those counselors can feel handcuffed by
structured instruments.
Forman: You have to be extremely talented
to go through a structured interview, even
one that is semi-structured, and maintain
a therapeutic alliance. Fully structured 
interviews have a tendency to become robo-
tic, when what clients want is someone who’s
going to listen and understand them—some-
one they can open up to.
Svikis:The way fully structured instruments
work, if you follow the administration guide-
lines, when a patient doesn’t understand
what you’re saying, you can only repeat the
question verbatim. You can’t add informa-
tion or paraphrase. That makes it hard to
establish empathy. It is easier to establish a
rapport with semi-structured instruments
like the ASI.
Another feature of fully structured instru-
ments that makes them aversive is that you
have to repeat all the same questions for each
potential drug of abuse. In a clinical setting
where the average person uses six or seven
substances, that makes for a very long and
tedious interview. It’s quite different from
using the instruments in an epidemiologi-
cal context with a focus on the general pop-
ulation, where most people use one or
two substances regularly or none at all.
Blaine: There is no question that it’s easier
to establish a relationship with a patient
with a less structured instrument than with
a more rigid one. Still, the very act of gath-
ering information shows that you are inter-
ested in finding out about a person’s prob-
lems. I think that builds rapport.
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Forman: In a clinical situation, no matter
what instrument or tool you use, patients
may not be ready to be frank about all their
issues in a first interview. Assessment is a
process, not something that’s done once 
and for all at intake.
Svikis: One good example is the group of
people who come to a program because of
a legal issue, such as an arrest for driving
while intoxicated. At intake, they tend to
minimize and deny problems, to the point
where their professed symptoms might not
meet criteria for any substance use disorder.
Two months into treatment, however, they
might be more willing to provide more infor-
mation about their alcohol and drug use.
Blaine:That’s where the rapport comes in.
Diagnosis and treatment planning
Blaine: The ASI, which is probably the most
widely used assessment instrument, includes
several domains besides alcohol and drugs
that help determine what kinds of services
the patient needs. All the other instruments
discussed in the article really focus on mak-
ing DSM-IV diagnoses of mental disorders.
In a clinical setting, it makes more sense to
start with a screener—say, the Hopkins
Symptom Checklist 90 (Lipman, Covi, and
Shapiro, 1979) or Brief Symptom Inventory
(Derogatis and Spencer, 1982)—than with
one of these highly complex instruments.
Then, if you need to make a diagnosis after
that, you can administer the appropriate
section of one of these interviews.
Svikis: In today’s drug treatment settings,
making a specific diagnosis of drug abuse
or drug dependence doesn’t usually change
what you’re going to do for a patient or how
you’re going to do it. To date, we have little
evidence that empirically based treatments
produce different outcomes for patients
with one of these diagnoses versus the other.
Forman: Most payers are interested only in
knowing, does this person need to be hos-
pitalized, and if not, does this person meet
the criteria for dependence in very gross
terms? For that, it’s sufficient to use a check-
list of the seven DSM-IV criteria, such as
the one developed by Dr. Robert Brooner
(for more information, contact Dr. Brooner
at RKBrooner@aol.com).
Blaine: Nevertheless, the information on
severity that these instruments tap into is
potentially useful. It is possible that people
on the high end of the severity spectrum will
benefit more from intense and different serv-
ices than those on the low end. One reason
we lack evidence for this is that research
tends to focus, rightly, on the people in
greater distress, those at the higher end.
Svikis: That’s true. When I ran a program
for pregnant drug-dependent women, the
women with lower severity indicators were
the ones most likely to leave treatment against
medical advice in the first couple of days.
Our clinical impression was that they self-
selected out because their addictions were
less severe than those of their peers, and the
program intensity level was too high for
them. They took a look around and said, “I
don’t need to be here, yet.”
Forman:I am sure the majority of treatment
providers would agree and would like to
match each patient’s level of care to the sever-
ity of his or her problem. However, in most
cases, programs’ resources are too constrained
to offer multiple levels of care. Usually,
the only level of care decision that gets made
is whether the patient should be treated in
rehab, an outpatient clinic, or a hospital.
Blaine: The article raises an important treat-
ment planning issue: that of distinguishing
the mood symptoms of withdrawal from
those of major depression. Programs often
deal with that by waiting 2 weeks to a month,
until the patient has finished the withdrawal
process, and then administering an instru-
ment like the Beck Depression Inventory
to see if the symptoms are still there.
Svikis:The issue of withdrawal versus depres-
sion is very complex. Many programs ask
counselors to make this distinction based
solely on the ASI, which covers only symp-
toms in the past 30 days. I believe additional
screening tools may improve the validity
and reliability of such decisions. Even in
research settings, we can’t always tease these
two entities apart. Among the difficulties is
the fact that the length of substance-related
mood symptoms can vary by substance.
Also, some outpatients continue to use drugs,
which can lead to a recurrence or exacer-
bation of such symptoms.
ASI issues
Svikis:I think this would be a good time to
evaluate how accurately the ASI is being
administered and whether it is being used
as intended when the field mandated its
adoption. A primary reason for having a
standardized tool across programs is to make
it possible for payers to compare programs
and see which ones have better retention
rates, whether client characteristics at base-
line are associated with different outcomes,
and so forth. That all sounds really good
in theory. In practice, as an ASI trainer, I’ve
seen that in a typical class with 30 coun-
selors, at least 7 or 8 will say they’ve been
using the instrument for 6 months or more
at their site, yet this is their first training. I’ve
also been struck by how few supervisors
attend training, and I wonder how they can
monitor the aptness with which it is used
for treatment planning without having been
trained. I am not sure we do the field a serv-
ice by telling people that you can compare
data across programs, when we’re not imple-
menting sufficient infrastructure to make
sure the instrument is being used in a way
that produces reliable and valid data. 
Forman:It is not easy to become proficient
with the ASI, and even under the best of
circumstances, interviewers can “drift” from
their training and begin to administer and
score the measure in ways that were not
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often don’t have time to review the results
and make good clinical judgments around
them. To address this problem, as the arti-
cle mentions, NIDA’s Blending Initiative
provides training materials for translating
information acquired with the ASI into 
treatment plans.
Svikis: There is now a patients’ self-
administered version of the ASI (www.
asimv.com), and Tom McLellan and Deni
Carise are currently testing a product that
takes the ASI data input from clinicians and
actually prints out a treatment plan. I think
those are great steps in the right direction.
Forman: The pressures on clinicians’ time
are so great that often the only way they can
do something new is to stop doing some-
thing else. I think any tool that patients can
self-administer has a much better chance of
being integrated into clinical practice.
Svikis: In the big picture, notwithstand-
ing the problems we’ve mentioned, the field
has taken a significant step forward with the
widespread adoption of the ASI. We now
collect at least a minimum quantity of data
on everybody concerning the domains that
have been identified to be most relevant for
treatment planning and treatment outcome.
This is a big accomplishment and a big step
forward.
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